Lycia Therapeutics

Lycia Therapeutics (Ticker: LYCA US) develops therapeutics designed to degrade disease-causing proteins outside cells. Its proprietary LYTAC platform is used to develop candidates designed to eliminate these proteins. LCA-0061 is designed to degrade IgE for allergic diseases, including food allergy, and is being tested in a Phase 1 trial involving participants with elevated IgE, including food-allergy patients. LCA-0321 is designed to selectively degrade autoantibodies associated with Graves’ disease and is being tested in a Phase 1 trial in patients with Graves’ disease.

For the 12 months ended June 30, 2026, the company reported revenue of $4.44 million and a net loss of $30.03 million. Lycia Therapeutics expects to list on Nasdaq on October 23, 2026. The base offering was upsized to 17,640,000 shares and priced at $18.00 per share, at the top of the original $16.00–$18.00 indicative range. At the confirmed price, the base offering represents $317.52 million in gross proceeds, excluding any unexercised over-allotment.

The offering's managers include Jefferies, TD Securities, and Evercore ISI.